Medigen Biotechnology Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Taipei Taiwan (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2001
NCT00068172
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Medigen Biotechnology Corporation | Medigen Vaccine Biologics | Medigen Vaccine Biologics Corp. | Medigen Vaccinology Corp.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Dengue (Phase 2)

Enterovirus Infections (Phase 3)

Influenza, Human (Phase 3)

Influenza in Birds (Phase 2)

Liver Neoplasms (Phase 3)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial APIs: 13